Recent advance in the development of novel, selective and potent FGFR inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recent advance in the development of novel, selective and potent FGFR inhibitors

Published:2020-01 Issue: Volume:186 Page:111884
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Liu Feng-Tao,Li Nian-Guang,Zhang Yan-Min,Xie Wu-Chen,Yang Si-Ping,Lu Tao,Shi Zhi-Hao

Funder

National Natural Science Foundation of China

National Natural Science Foundation Youth Project of China

Natural Science Foundation Youth Project of Jiangsu Province

State Key Laboratory Innovation Research and Cultivation Fund

China Pharmaceutical University

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference84 articles.

1. Cancer treatment and survivorship statistics;Miller;CA A Cancer J. Clin.,2016

2. Global cancer statistics;Parkin;CA A Cancer J. Clin.,2012

3. A history of cancer chemotherapy;DeVita;Cancer Res.,2008

4. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides

5. Protein kinase inhibitors in drug discovery;Parang;Pharm. Sci. Encycl,2010

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations;Bioorganic Chemistry;2024-09

2. State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies;Current Opinion in Oncology;2024-05-07

3. Patient tissue-derived FGFR4-variant and wild-type colorectal cancer organoid development and anticancer drug sensitivity testing;Heliyon;2024-05

4. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality;Acta Pharmaceutica;2024-03-01

5. Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond;Journal of Gastric Cancer;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3